VolitionRX (NYSEAMERICAN:VNRX) Shares Cross Below 50-Day Moving Average – Should You Sell?

VolitionRX Limited (NYSEAMERICAN:VNRX) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.17 and traded as low as $2.76. VolitionRX shares last traded at $3.13, with a volume of 513,751 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. HC Wainwright cut their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Finally, Citigroup cut shares of VolitionRX to a “hold” rating in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, VolitionRX currently has an average rating of “Moderate Buy” and a consensus price target of $46.67.

VolitionRX Stock Up 15.9%

The stock’s fifty day moving average price is $3.17 and its 200 day moving average price is $4.75. The stock has a market cap of $26.07 million, a PE ratio of -0.75 and a beta of 1.03.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The firm had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.52 million. On average, equities research analysts expect that VolitionRX Limited will post -2.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VolitionRX

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX during the fourth quarter valued at approximately $34,000. Virtu Financial LLC purchased a new stake in shares of VolitionRX during the third quarter valued at approximately $28,000. Jane Street Group LLC purchased a new stake in shares of VolitionRX during the fourth quarter valued at approximately $28,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in shares of VolitionRX during the second quarter valued at approximately $52,000. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.